Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Westin

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2024
Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patientsHannes Hegmar, Axel Wester, Soo Aleman, et al.
Plos One|April 5, 2014
A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisMagdalena Ydreborg, Vera Lisovskaja, Martin Lagging, et al.
Plos One|May 12, 2016
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionJesper Waldenström, Johan Westin, Kristina Nyström, et al.
Genome Biology|June 14, 2021
Leveraging breeding programs and genomic data in Norway spruce (Picea abies L. Karst) for GWAS analysisZhi-Qiang Chen, Yanjun Zan, Pascal Milesi, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
The New Phytologist|September 12, 2022
Teasing apart the joint effect of demography and natural selection in the birth of a contact zoneLili Li, Pascal Milesi, Mathieu Tiret, et al.
Plos One|June 2, 2012
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Åsa Alsiö, Karolina Rembeck, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|February 13, 2014
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, et al.
BMC Medical Genetics|September 18, 2012
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infectionKarolina Rembeck, Cristina Maglio, Martin Lagging, et al.
Journal of Hepatology|August 15, 2006
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trialHans Orlent, Bettina E Hansen, Marc Willems, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2024
Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patientsHannes Hegmar, Axel Wester, Soo Aleman, et al.
Plos One|April 5, 2014
A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisMagdalena Ydreborg, Vera Lisovskaja, Martin Lagging, et al.
Plos One|May 12, 2016
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionJesper Waldenström, Johan Westin, Kristina Nyström, et al.
Genome Biology|June 14, 2021
Leveraging breeding programs and genomic data in Norway spruce (Picea abies L. Karst) for GWAS analysisZhi-Qiang Chen, Yanjun Zan, Pascal Milesi, et al.
Hepatology (Baltimore, Md.)|February 27, 2010
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh, Asa Alsiö, Paolo Pugnale, et al.
The New Phytologist|September 12, 2022
Teasing apart the joint effect of demography and natural selection in the birth of a contact zoneLili Li, Pascal Milesi, Mathieu Tiret, et al.
Plos One|June 2, 2012
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Åsa Alsiö, Karolina Rembeck, Galia Askarieh, et al.
Hepatology (Baltimore, Md.)|February 13, 2014
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3Karolina Rembeck, Jesper Waldenström, Kristoffer Hellstrand, et al.
BMC Medical Genetics|September 18, 2012
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infectionKarolina Rembeck, Cristina Maglio, Martin Lagging, et al.
Journal of Hepatology|August 15, 2006
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trialHans Orlent, Bettina E Hansen, Marc Willems, et al.
Pageof 10